{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T20:02:22Z","timestamp":1781726542445,"version":"3.54.5"},"reference-count":157,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"DOI":"10.1007\/s11010-026-05505-1","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T09:51:16Z","timestamp":1771494676000},"page":"1925-1946","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Current progress in pathway-targeted therapeutics for Alzheimer\u2019s disease: mechanistic insights and windows of opportunity"],"prefix":"10.1007","volume":"481","author":[{"given":"Habab Ali","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnoor","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tooba","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Imran","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"5505_CR1","unstructured":"Dementia statistics | Alzheimer's Disease International (ADI). 2024; Available from: https:\/\/www.alzint.org\/about\/dementia-facts-figures\/dementia-statistics\/#:~:text=Someone%20in%20the%20world%20develops,Asian%20and%20western%20Pacific%20neighbours."},{"issue":"1","key":"5505_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.14336\/ad.2023.0608","volume":"15","author":"M Nasb","year":"2024","unstructured":"Nasb M, Tao W, Chen N (2024) Alzheimer\u2019s disease puzzle: delving into pathogenesis hypotheses. Aging Dis 15(1):43\u201373. https:\/\/doi.org\/10.14336\/ad.2023.0608","journal-title":"Aging Dis"},{"key":"5505_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.837649","author":"C-X Gong","year":"2022","unstructured":"Gong C-X et al (2022) Multi-targets: an unconventional drug development strategy for Alzheimer\u2019s disease. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2022.837649","journal-title":"Front Aging Neurosci"},{"key":"5505_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2024.10.014","author":"RJ Castellani","year":"2024","unstructured":"Castellani RJ et al (2024) The amyloid cascade hypothesis: a conclusion in search of support. Am J Pathol. https:\/\/doi.org\/10.1016\/j.ajpath.2024.10.014","journal-title":"Am J Pathol"},{"issue":"4","key":"5505_CR5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3233\/jad-160612","volume":"57","author":"R Rajmohan","year":"2017","unstructured":"Rajmohan R, Reddy PH (2017) Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer\u2019s disease neurons. J Alzheimers Dis 57(4):975\u2013999. https:\/\/doi.org\/10.3233\/jad-160612","journal-title":"J Alzheimers Dis"},{"key":"5505_CR6","doi-asserted-by":"publisher","DOI":"10.1172\/jci168553","author":"N Samudra","year":"2023","unstructured":"Samudra N et al (2023) Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues. J clin investig. https:\/\/doi.org\/10.1172\/jci168553","journal-title":"J clin investig"},{"issue":"2","key":"5505_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3390\/biomedicines13020279","volume":"13","author":"D Dias","year":"2025","unstructured":"Dias D, Socodato R (2025) Beyond amyloid and tau: the critical role of microglia in Alzheimer\u2019s disease therapeutics. Biomedicines 13(2):279","journal-title":"Biomedicines"},{"issue":"1","key":"5505_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01911-3","volume":"9","author":"J Zhang","year":"2024","unstructured":"Zhang J et al (2024) Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther 9(1):211. https:\/\/doi.org\/10.1038\/s41392-024-01911-3","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"5505_CR9","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/ibra.12098","volume":"9","author":"B-C Tang","year":"2023","unstructured":"Tang B-C, Wang Y-T, Ren J (2023) Basic information about memantine and its treatment of Alzheimer\u2019s disease and other clinical applications. iBrain 9(3):340\u2013348. https:\/\/doi.org\/10.1002\/ibra.12098","journal-title":"iBrain"},{"issue":"3","key":"5505_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jama.291.3.317","volume":"291","author":"PN Tariot","year":"2004","unstructured":"Tariot PN et al (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezilA randomized controlled trial. JAMA 291(3):317\u2013324. https:\/\/doi.org\/10.1001\/jama.291.3.317","journal-title":"JAMA"},{"issue":"2","key":"5505_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1124\/jpet.121.001071","volume":"382","author":"H Rosenbrock","year":"2022","unstructured":"Rosenbrock H et al (2022) Effects of the glycine transporter-1 inhibitor Iclepertin (BI 425809) on sensory processing, neural network function, and cognition in animal models related to schizophrenia. J Pharmacol Exp Ther 382(2):223\u2013232. https:\/\/doi.org\/10.1124\/jpet.121.001071","journal-title":"J Pharmacol Exp Ther"},{"issue":"647","key":"5505_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abi8593","volume":"14","author":"J Spurrier","year":"2022","unstructured":"Spurrier J et al (2022) Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q. Sci Transl Med 14(647):eabi8593. https:\/\/doi.org\/10.1126\/scitranslmed.abi8593","journal-title":"Sci Transl Med"},{"issue":"1","key":"5505_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-023-00976-6","volume":"30","author":"LK Huang","year":"2023","unstructured":"Huang LK et al (2023) Clinical trials of new drugs for Alzheimer disease: a 2020-2023 update. J Biomed Sci 30(1):83. https:\/\/doi.org\/10.1186\/s12929-023-00976-6","journal-title":"J Biomed Sci"},{"key":"5505_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100657","volume":"29","author":"L J\u00f6nsson","year":"2023","unstructured":"J\u00f6nsson L et al (2023) The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer\u2019s disease: an EADC-EC viewpoint. Lancet Reg Health Eur 29:100657. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100657","journal-title":"Lancet Reg Health Eur"},{"key":"5505_CR15","unstructured":"Organization, W.H., (2017) Global action plan on the public health response to dementia 2017\u20132025, in Global action plan on the public health response to dementia 2017\u20132025."},{"issue":"3","key":"5505_CR37","doi-asserted-by":"publisher","first-page":"164","DOI":"10.35772\/ghm.2024.01033","volume":"6","author":"AK Ghosh","year":"2024","unstructured":"Ghosh AK (2024) BACE1 inhibitor drugs for the treatment of Alzheimer\u2019s disease: lessons learned, challenges to overcome, and future prospects(\u2020). Glob Health Med 6(3):164\u2013168. https:\/\/doi.org\/10.35772\/ghm.2024.01033","journal-title":"Glob Health Med"},{"issue":"15","key":"5505_CR38","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","volume":"380","author":"MF Egan","year":"2019","unstructured":"Egan MF et al (2019) Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease. N Engl J Med 380(15):1408\u20131420","journal-title":"N Engl J Med"},{"issue":"3","key":"5505_CR39","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1001\/jamaneurol.2020.4857","volume":"78","author":"R Sperling","year":"2021","unstructured":"Sperling R et al (2021) Findings of efficacy, safety, and biomarker outcomes of atabecestat in preclinical Alzheimer disease: a truncated randomized phase 2b\/3 clinical trial. JAMA Neurol 78(3):293\u2013301","journal-title":"JAMA Neurol"},{"issue":"11","key":"5505_CR40","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1002\/alz.12164","volume":"16","author":"AM Wessels","year":"2020","unstructured":"Wessels AM et al (2020) Cognitive outcomes in trials of two BACE inhibitors in Alzheimer\u2019s disease. Alzheimers Dement 16(11):1483\u20131492","journal-title":"Alzheimers Dement"},{"issue":"3","key":"5505_CR41","doi-asserted-by":"publisher","first-page":"Fso11","DOI":"10.4155\/fso.15.9","volume":"1","author":"R MacLeod","year":"2015","unstructured":"MacLeod R et al (2015) The role and therapeutic targeting of \u03b1-, \u03b2- and \u03b3-secretase in Alzheimer\u2019s disease. Future Sci OA 1(3):Fso11. https:\/\/doi.org\/10.4155\/fso.15.9","journal-title":"Future Sci OA"},{"issue":"1","key":"5505_CR42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.celrep.2017.09.032","volume":"21","author":"S Tagami","year":"2017","unstructured":"Tagami S et al (2017) Semagacestat is a pseudo-inhibitor of \u03b3-secretase. Cell Rep 21(1):259\u2013273","journal-title":"Cell Rep"},{"issue":"11","key":"5505_CR43","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1001\/jamaneurol.2015.0607","volume":"72","author":"V Coric","year":"2015","unstructured":"Coric V et al (2015) Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial. JAMA Neurol 72(11):1324\u20131333. https:\/\/doi.org\/10.1001\/jamaneurol.2015.0607","journal-title":"JAMA Neurol"},{"issue":"22","key":"5505_CR44","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1016\/j.molcel.2023.10.029","volume":"83","author":"P Hou","year":"2023","unstructured":"Hou P et al (2023) The \u03b3-secretase substrate proteome and its role in cell signaling regulation. Mol Cell 83(22):4106-4122.e10. https:\/\/doi.org\/10.1016\/j.molcel.2023.10.029","journal-title":"Mol Cell"},{"issue":"4","key":"5505_CR45","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody RS et al (2013) A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N Engl J Med 369(4):341\u2013350. https:\/\/doi.org\/10.1056\/NEJMoa1210951","journal-title":"N Engl J Med"},{"key":"5505_CR46","doi-asserted-by":"publisher","first-page":"1279740","DOI":"10.3389\/fnmol.2023.1279740","volume":"16","author":"G Nordvall","year":"2023","unstructured":"Nordvall G, Lundkvist J, Sandin J (2023) Gamma-secretase modulators: a promising route for the treatment of Alzheimer\u2019s disease. Front Mol Neurosci 16:1279740. https:\/\/doi.org\/10.3389\/fnmol.2023.1279740","journal-title":"Front Mol Neurosci"},{"issue":"9","key":"5505_CR47","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1039\/D0MD00196A","volume":"11","author":"S Mekala","year":"2020","unstructured":"Mekala S, Nelson G, Li Y-M (2020) Recent developments of small molecule \u03b3-secretase modulators for Alzheimer\u2019s disease. RSC Medicinal Chemistry 11(9):1003\u20131022","journal-title":"RSC Medicinal Chemistry"},{"issue":"23","key":"5505_CR48","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1001\/jama.2009.1866","volume":"302","author":"RC Green","year":"2009","unstructured":"Green RC et al (2009) Effect of Tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial. JAMA 302(23):2557\u20132564. https:\/\/doi.org\/10.1001\/jama.2009.1866","journal-title":"JAMA"},{"issue":"39","key":"5505_CR49","doi-asserted-by":"publisher","first-page":"32640","DOI":"10.1074\/jbc.M112.376541","volume":"287","author":"J Wanngren","year":"2012","unstructured":"Wanngren J et al (2012) Second generation \u03b3-secretase modulators exhibit different modulation of Notch \u03b2 and A\u03b2 production. J Biol Chem 287(39):32640\u201332650","journal-title":"J Biol Chem"},{"key":"5505_CR50","doi-asserted-by":"publisher","first-page":"S242","DOI":"10.1016\/j.jalz.2010.05.787","volume":"6","author":"T Hashimoto","year":"2010","unstructured":"Hashimoto T et al (2010) P1\u2013236: E2012: a novel gamma-secretase modulator-pharmacology part. Alzheimers Dement 6:S242\u2013S242","journal-title":"Alzheimers Dement"},{"key":"5505_CR51","doi-asserted-by":"publisher","first-page":"S574","DOI":"10.1016\/j.jalz.2010.05.1958","volume":"6","author":"C Nagy","year":"2010","unstructured":"Nagy C et al (2010) P3\u2010415: E2012, a novel gamma\u2010secretase modulator, decreases plasma amyloid\u2010beta (A\u03b2) levels in humans. Alzheimers Dement 6:S574\u2013S574","journal-title":"Alzheimers Dement"},{"key":"5505_CR52","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202560","author":"KD Rynearson","year":"2021","unstructured":"Rynearson KD et al (2021) Preclinical validation of a potent \u03b3-secretase modulator for Alzheimer\u2019s disease prevention. J Exp Med. https:\/\/doi.org\/10.1084\/jem.20202560","journal-title":"J Exp Med"},{"issue":"5","key":"5505_CR53","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jcph.249","volume":"54","author":"Y Yu","year":"2014","unstructured":"Yu Y et al (2014) Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel \u03b3-secretase modulator, E2212, in healthy human subjects. J Clin Pharmacol 54(5):528\u2013536. https:\/\/doi.org\/10.1002\/jcph.249","journal-title":"J Clin Pharmacol"},{"key":"5505_CR54","doi-asserted-by":"crossref","unstructured":"Rynearson, K.D., et al., (2021) Preclinical validation of a potent \u03b3-secretase modulator for Alzheimer\u2019s disease prevention. Journal of Experimental Medicine, 218(4)","DOI":"10.1084\/jem.20202560"},{"issue":"Suppl 8","key":"5505_CR55","volume":"20","author":"T Mueggler","year":"2025","unstructured":"Mueggler T et al (2025) Pharmacodynamic effect of a new \u03b3-secretase modulator, RG6289, on CSF amyloid-\u03b2 peptides in a randomized Phase I study. Alzheimers Dement 20(Suppl 8):e095213","journal-title":"Alzheimers Dement"},{"key":"5505_CR56","unstructured":"FDA Grants Accelerated Approval for Alzheimer\u2019s Disease Treatment. 2021 [cited 2021; Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-disease-treatment."},{"issue":"4","key":"5505_CR57","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.3233\/JAD-215275","volume":"84","author":"PF H\u00f8ilund-Carlsen","year":"2021","unstructured":"H\u00f8ilund-Carlsen PF, Alavi A (2021) Aducanumab (marketed as Aduhelm) approval is likely based on misinterpretation of PET imaging data. J Alzheimers Dis 84(4):1457\u20131460","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"5505_CR58","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CHv Dyck","year":"2023","unstructured":"Dyck CHv et al (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"issue":"18","key":"5505_CR59","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA et al (2021) Donanemab in early Alzheimer\u2019s disease. N Engl J Med 384(18):1691\u20131704","journal-title":"N Engl J Med"},{"issue":"11","key":"5505_CR60","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1080\/14712598.2024.2416947","volume":"24","author":"A Chhabra","year":"2024","unstructured":"Chhabra A et al (2024) A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer\u2019s disease. Expert Opin Biol Ther 24(11):1261\u20131269","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"5505_CR61","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41591-021-01456-w","volume":"27","author":"TA Pascoal","year":"2021","unstructured":"Pascoal TA et al (2021) Microglial activation and tau propagate jointly across Braak stages. Nat Med 27(9):1592\u20131599. https:\/\/doi.org\/10.1038\/s41591-021-01456-w","journal-title":"Nat Med"},{"issue":"11","key":"5505_CR62","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/nn.4132","volume":"18","author":"H Asai","year":"2015","unstructured":"Asai H et al (2015) Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci 18(11):1584\u20131593. https:\/\/doi.org\/10.1038\/nn.4132","journal-title":"Nat Neurosci"},{"issue":"10","key":"5505_CR63","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1111\/febs.70021","volume":"292","author":"RX Santos","year":"2025","unstructured":"Santos RX et al (2025) Hydromethylthionine sustains truncated tau-dependent inflammation-lowering effects in mouse brain. The FEBS J 292(10):2602\u20132623","journal-title":"The FEBS J"},{"issue":"1","key":"5505_CR64","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3233\/JAD-170560","volume":"61","author":"GK Wilcock","year":"2017","unstructured":"Wilcock GK et al (2017) Potential of low dose leuco-methylthioninium bis (hydromethanesulphonate)(LMTM) monotherapy for treatment of mild Alzheimer\u2019s disease: cohort analysis as modified primary outcome in a phase III clinical trial. J Alzheimers Dis 61(1):435\u2013457","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"5505_CR65","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3233\/jad-170188","volume":"58","author":"M Tang","year":"2017","unstructured":"Tang M, Taghibiglou C (2017) The mechanisms of action of curcumin in Alzheimer\u2019s disease. J Alzheimers Dis 58(4):1003\u20131016. https:\/\/doi.org\/10.3233\/jad-170188","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"5505_CR66","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/d41573-020-00217-7","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard A (2021) Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating. Nat Rev Drug Discov 20(1):3\u20136","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"5505_CR67","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1089\/ipm.11.02.11","volume":"11","author":"H Albert","year":"2024","unstructured":"Albert H (2024) Beginning a new era of precision Alzheimer\u2019s therapeutics. Inside Precis Med 11(2):36\u201341","journal-title":"Inside Precis Med"},{"key":"5505_CR68","doi-asserted-by":"crossref","unstructured":"Sadhu, C., et al. (2024) Pharmacokinetics and Pharmacodynamics of an Antibody Targeting Pathological Tau for the Treatment of Alzheimer\u2019s Disease: Nonclinical Studies in P301S Mice and Cynomolgus Macaques. in Alzheimer's Association International Conference. ALZ.","DOI":"10.1002\/alz.091630"},{"issue":"3","key":"5505_CR69","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/biof.1930","volume":"49","author":"G Montalto","year":"2023","unstructured":"Montalto G, Ricciarelli R (2023) Tau, tau kinases, and tauopathies: an updated overview. BioFactors 49(3):502\u2013511","journal-title":"BioFactors"},{"key":"5505_CR70","unstructured":"Gildengers, A., et al. Lithium As a Treatment to Prevent Impairment of Cognition in Elders (LATTICE). in Neuropsychopharmacology. 2017. NATURE PUBLISHING GROUP MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND."},{"issue":"1","key":"5505_CR71","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/jad-141959","volume":"45","author":"S Lovestone","year":"2015","unstructured":"Lovestone S et al (2015) A phase II trial of tideglusib in Alzheimer\u2019s disease. J Alzheimers Dis 45(1):75\u201388. https:\/\/doi.org\/10.3233\/jad-141959","journal-title":"J Alzheimers Dis"},{"key":"5505_CR72","doi-asserted-by":"crossref","unstructured":"Gao, S., et al., (2024) LncRNA ENST00000440246. 1 Promotes Alzheimer\u2019s Disease Progression by Targeting PP2A. Biochemical Genetics,. 62(3): p. 2100\u20132116","DOI":"10.1007\/s10528-023-10552-0"},{"issue":"3","key":"5505_CR73","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202101625R","volume":"36","author":"Y Zhou","year":"2022","unstructured":"Zhou Y et al (2022) ChK1 activation induces reactive astrogliosis through CIP2A\/PP2A\/STAT3 pathway in Alzheimer\u2019s disease. FASEB J 36(3):e22209","journal-title":"FASEB J"},{"issue":"12","key":"5505_CR74","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1038\/s43587-023-00523-w","volume":"3","author":"M Shulman","year":"2023","unstructured":"Shulman M et al (2023) TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer\u2019s disease. Nat Aging 3(12):1591\u20131601","journal-title":"Nat Aging"},{"issue":"6","key":"5505_CR75","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/brain\/awad024","volume":"146","author":"H Florian","year":"2023","unstructured":"Florian H et al (2023) Tilavonemab in early Alzheimer\u2019s disease: results from a phase 2, randomized, double-blind study. Brain 146(6):2275\u20132284","journal-title":"Brain"},{"issue":"14","key":"5505_CR76","doi-asserted-by":"publisher","first-page":"e1391","DOI":"10.1212\/WNL.0000000000207663","volume":"101","author":"C Monteiro","year":"2023","unstructured":"Monteiro C et al (2023) Randomized phase II study of the safety and efficacy of semorinemab in participants with mild-to-moderate Alzheimer disease: Lauriet. Neurology 101(14):e1391\u2013e1401","journal-title":"Neurology"},{"issue":"6","key":"5505_CR77","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR et al (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330(6):512\u2013527","journal-title":"JAMA"},{"issue":"6","key":"5505_CR78","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","volume":"1","author":"P Novak","year":"2021","unstructured":"Novak P et al (2021) ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer\u2019s disease. Nat Aging 1(6):521\u2013534","journal-title":"Nat Aging"},{"key":"5505_CR79","doi-asserted-by":"publisher","first-page":"P260","DOI":"10.1016\/j.jalz.2016.06.468","volume":"12","author":"M Pihlgren","year":"2016","unstructured":"Pihlgren M et al (2016) O2\u201313-03: efficacy of ACI-35, a liposomal anti-phospho tau vaccine in two different mouse models of Alzheimer\u2019s disease. Alzheimers Dement 12:P260\u2013P261","journal-title":"Alzheimers Dement"},{"key":"5505_CR80","unstructured":"Heneka, M.T., et al., Neuroinflammation in Alzheimer disease. Nature Reviews Immunology, 2024: p. 1\u201332"},{"issue":"4","key":"5505_CR81","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3390\/neuroglia5040029","volume":"5","author":"S Shah","year":"2024","unstructured":"Shah S, Jain H (2024) Microglia-associated neuroinflammation in Alzheimer\u2019s disease and its therapeutic potential. Neuroglia 5(4):452\u2013466","journal-title":"Neuroglia"},{"key":"5505_CR82","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13195-025-01700-2","volume":"17","author":"JI Dijkstra","year":"2025","unstructured":"Dijkstra JI et al (2025) TREM2 risk variants and associated endophenotypes in alzheimer\u2019s disease. Alzheimers Res Ther 17:57","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"5505_CR83","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s13195-024-01599-1","volume":"16","author":"H Long","year":"2024","unstructured":"Long H et al (2024) Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer\u2019s disease. Alzheimer\u2019s Research & Therapy 16(1):235","journal-title":"Alzheimer's Research & Therapy"},{"issue":"1","key":"5505_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01599-1","volume":"16","author":"H Long","year":"2024","unstructured":"Long H et al (2024) Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer\u2019s disease. Alzheimers Res Ther 16(1):235. https:\/\/doi.org\/10.1186\/s13195-024-01599-1","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"5505_CR85","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221850","volume":"220","author":"G Carling","year":"2022","unstructured":"Carling G, Luo W, Gan L (2022) Friend turned foe: TREM2 agonist in battles against tau. J Exp Med 220(1):e20221850","journal-title":"J Exp Med"},{"issue":"11","key":"5505_CR86","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.3390\/cells12111549","volume":"12","author":"M Fassler","year":"2023","unstructured":"Fassler M, Benaim C, George J (2023) TREM2 agonism with a monoclonal antibody attenuates tau pathology and neurodegeneration. Cells 12(11):1549","journal-title":"Cells"},{"issue":"1","key":"5505_CR87","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s40478-021-01204-8","volume":"9","author":"C Lodder","year":"2021","unstructured":"Lodder C et al (2021) CSF1R inhibition rescues tau pathology and neurodegeneration in an A\/T\/N model with combined AD pathologies, while preserving plaque associated microglia. Acta Neuropathol Commun 9(1):108","journal-title":"Acta Neuropathol Commun"},{"key":"5505_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-018-0244-x","volume":"13","author":"J Sosna","year":"2018","unstructured":"Sosna J et al (2018) Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer\u2019s disease. Mol Neurodegener 13:1\u201311","journal-title":"Mol Neurodegener"},{"key":"5505_CR89","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-024-01598-6","author":"V Bhardwaj","year":"2024","unstructured":"Bhardwaj V et al (2024) Shedding light on microglial dysregulation in Alzheimer\u2019s disease: exploring molecular mechanisms and therapeutic avenues. Inflammopharmacology. https:\/\/doi.org\/10.1007\/s10787-024-01598-6","journal-title":"Inflammopharmacology"},{"key":"5505_CR90","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-021-00889-6","author":"R Dhapola","year":"2021","unstructured":"Dhapola R et al (2021) Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer\u2019s disease. Inflammopharmacology. https:\/\/doi.org\/10.1007\/s10787-021-00889-6","journal-title":"Inflammopharmacology"},{"key":"5505_CR91","doi-asserted-by":"crossref","unstructured":"Hershey, L.A. and R.B. Lipton, Naproxen for presymptomatic Alzheimer disease: is this the end, or shall we try again? 2019, Lippincott Williams & Wilkins Hagerstown, MD. p. 829\u2013830.","DOI":"10.1212\/WNL.0000000000007233"},{"issue":"18","key":"5505_CR92","doi-asserted-by":"publisher","first-page":"e2070","DOI":"10.1212\/WNL.0000000000007232","volume":"92","author":"P-F Meyer","year":"2019","unstructured":"Meyer P-F et al (2019) INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease. Neurology 92(18):e2070\u2013e2080","journal-title":"Neurology"},{"key":"5505_CR93","doi-asserted-by":"crossref","unstructured":"Janakiraman, U., et al., (2022) SELECTIVE INHIBITION OF SOLUBLE TNF ATTENUATES HIPPOCAMPAL NEUROINFLAMMATION AND PSD-95 EXPRESSION TO IMPROVE NEUROLOGICAL FUNCTIONS IN A RAT MODEL OF GULF WAR ILLNESS. bioRxiv p. 2022.11. 28.518204","DOI":"10.1101\/2022.11.28.518204"},{"key":"5505_CR94","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.neurobiolaging.2016.07.009","volume":"47","author":"C Cavanagh","year":"2016","unstructured":"Cavanagh C et al (2016) Inhibiting tumor necrosis factor-\u03b1 before amyloidosis prevents synaptic deficits in an Alzheimer\u2019s disease model. Neurobiol Aging 47:41\u201349","journal-title":"Neurobiol Aging"},{"key":"5505_CR95","doi-asserted-by":"publisher","DOI":"10.1002\/alz.083229","volume":"19","author":"P Pope","year":"2023","unstructured":"Pope P et al (2023) Clinical and biomarker correlates of region-specific diffusion MRI metrics in a short-term, phase 1b clinical trial for XPro1595 in Alzheimer\u2019s disease. Alzheimers Dement 19:e083229","journal-title":"Alzheimers Dement"},{"key":"5505_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.845185","volume":"13","author":"T Liang","year":"2022","unstructured":"Liang T et al (2022) The role of NLRP3 inflammasome in Alzheimer\u2019s disease and potential therapeutic targets. Front Pharmacol 13:845185. https:\/\/doi.org\/10.3389\/fphar.2022.845185","journal-title":"Front Pharmacol"},{"issue":"50","key":"5505_CR97","doi-asserted-by":"publisher","first-page":"32145","DOI":"10.1073\/pnas.2009680117","volume":"117","author":"N Lonnemann","year":"2020","unstructured":"Lonnemann N et al (2020) The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci U S A 117(50):32145\u201332154","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5505_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.990469","volume":"13","author":"JF Cao","year":"2022","unstructured":"Cao JF et al (2022) Exploring the mechanism of action of dapansutrile in the treatment of gouty arthritis based on molecular docking and molecular dynamics. Front Physiol 13:990469. https:\/\/doi.org\/10.3389\/fphys.2022.990469","journal-title":"Front Physiol"},{"issue":"18","key":"5505_CR99","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1021\/acschemneuro.4c00205","volume":"15","author":"T Retinasamy","year":"2024","unstructured":"Retinasamy T et al (2024) Repurposing Anakinra for Alzheimer\u2019s disease: the in vitro and in vivo effects of Anakinra on LPS-and AC-induced neuroinflammation. ACS Chem Neurosci 15(18):3298\u20133310","journal-title":"ACS Chem Neurosci"},{"key":"5505_CR100","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.neuroscience.2021.11.001","volume":"484","author":"Y Li","year":"2022","unstructured":"Li Y et al (2022) Etanercept reduces neuron injury and neuroinflammation via inactivating c-Jun N-terminal kinase and nuclear factor-\u03baB pathways in Alzheimer\u2019s disease: an in vitro and in vivo investigation. Neuroscience 484:140\u2013150","journal-title":"Neuroscience"},{"issue":"1","key":"5505_CR101","doi-asserted-by":"publisher","first-page":"5308","DOI":"10.1038\/s41467-022-32944-3","volume":"13","author":"Y Jiang","year":"2022","unstructured":"Jiang Y et al (2022) Preclinical and randomized clinical evaluation of the p38\u03b1 kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration. Nat Commun 13(1):5308","journal-title":"Nat Commun"},{"issue":"3","key":"5505_CR102","doi-asserted-by":"publisher","first-page":"549","DOI":"10.14283\/jpad.2024.36","volume":"11","author":"ND Prins","year":"2024","unstructured":"Prins ND et al (2024) Phase 2A learnings incorporated into RewinD-LB, a phase 2B clinical trial of neflamapimod in dementia with Lewy bodies. J Prev Alzheimers Dis 11(3):549\u2013557. https:\/\/doi.org\/10.14283\/jpad.2024.36","journal-title":"J Prev Alzheimers Dis"},{"key":"5505_CR103","doi-asserted-by":"crossref","unstructured":"Galvin, J., et al. (2025) Efficacy and Safety of the RewinD-LB Phase 2b Clinical Trial of Neflamapimod in Dementia With Lewy Bodies (DLB)(P8\u20133.002). in Neurology. 2025. Lippincott Williams & Wilkins Hagerstown, MD.","DOI":"10.1212\/WNL.0000000000211390"},{"issue":"1","key":"5505_CR104","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12158","volume":"7","author":"H Potter","year":"2021","unstructured":"Potter H et al (2021) Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer\u2019s disease. Alzheimers Dement (N Y) 7(1):e12158","journal-title":"Alzheimers Dement (N Y)"},{"issue":"12","key":"5505_CR105","doi-asserted-by":"publisher","first-page":"8364","DOI":"10.1007\/s12035-019-01684-9","volume":"56","author":"R Velazquez","year":"2019","unstructured":"Velazquez R et al (2019) Chronic Dyrk1 inhibition delays the onset of AD-like pathology in 3xTg-AD mice. Mol Neurobiol 56(12):8364\u20138375. https:\/\/doi.org\/10.1007\/s12035-019-01684-9","journal-title":"Mol Neurobiol"},{"issue":"3","key":"5505_CR106","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3233\/JAD-2012-120982","volume":"33","author":"SD Girard","year":"2013","unstructured":"Girard SD et al (2013) Evidence for early cognitive impairment related to frontal cortex in the 5XFAD mouse model of Alzheimer\u2019s disease. J Alzheimers Dis 33(3):781\u2013796","journal-title":"J Alzheimers Dis"},{"key":"5505_CR107","doi-asserted-by":"crossref","unstructured":"Homolak, J., et al., (2025) Species-specific sensitivity to intracerebroventricular streptozotocin in rats and mice highlights pathways and proteins relevant to Alzheimer\u2019s disease: J. Homolak et al. Journal of Neural Transmission, 2025: p. 1\u201320","DOI":"10.1007\/s00702-025-02952-w"},{"issue":"12","key":"5505_CR108","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.2174\/1568026620666200106125910","volume":"20","author":"AA Turab Naqvi","year":"2020","unstructured":"Turab Naqvi AA, Hasan GM, Hassan MI (2020) Targeting tau hyperphosphorylation via kinase inhibition: strategy to address Alzheimer\u2019s disease. Curr Top Med Chem 20(12):1059\u20131073","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"5505_CR109","doi-asserted-by":"publisher","first-page":"2304545","DOI":"10.1002\/advs.202304545","volume":"11","author":"P Mondal","year":"2024","unstructured":"Mondal P et al (2024) Structure-based discovery of a small molecule inhibitor of histone deacetylase 6 (HDAC6) that significantly reduces Alzheimer\u2019s disease neuropathology. Adv Sci 11(1):2304545","journal-title":"Adv Sci"},{"issue":"4","key":"5505_CR110","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1177\/08919887211044746","volume":"35","author":"AL Knorz","year":"2022","unstructured":"Knorz AL, Quante A (2022) Alzheimer\u2019s disease: efficacy of mono-and combination therapy. A systematic review. J Geriatr Psychiatry Neurol 35(4):475\u2013486","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"5","key":"5505_CR111","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1093\/ajh\/hpab032","volume":"34","author":"EO Miller","year":"2021","unstructured":"Miller EO, Bisognano JD (2021) Combo therapy in hypertension: still more to ACCOMPLISH after all these years. Am J Hypertens 34(5):459\u2013462","journal-title":"Am J Hypertens"},{"issue":"6","key":"5505_CR112","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/s41591-022-01815-1","volume":"28","author":"B Julg","year":"2022","unstructured":"Julg B et al (2022) Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat Med 28(6):1288\u20131296","journal-title":"Nat Med"},{"issue":"5","key":"5505_CR113","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1002\/med.21699","volume":"41","author":"C Albertini","year":"2021","unstructured":"Albertini C et al (2021) From combinations to multitarget-directed ligands: A continuum in Alzheimer\u2019s disease polypharmacology. Med Res Rev 41(5):2606\u20132633","journal-title":"Med Res Rev"},{"issue":"4","key":"5505_CR115","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3233\/JAD-215680","volume":"87","author":"A Salehipour","year":"2022","unstructured":"Salehipour A et al (2022) Combination therapy in Alzheimer\u2019s disease: is it time? J Alzheimers Dis 87(4):1433\u20131449","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"5505_CR120","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10020-025-01101-z","volume":"31","author":"X Meng","year":"2025","unstructured":"Meng X et al (2025) Type 3 diabetes and metabolic reprogramming of brain neurons: causes and therapeutic strategies. Mol Med 31(1):61","journal-title":"Mol Med"},{"issue":"1","key":"5505_CR121","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00853-0","volume":"13","author":"M Vargas-Soria","year":"2021","unstructured":"Vargas-Soria M et al (2021) Role of liraglutide in Alzheimer\u2019s disease pathology. Alzheimers Res Ther 13(1):112","journal-title":"Alzheimers Res Ther"},{"key":"5505_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109716","volume":"240","author":"Z-J Wang","year":"2023","unstructured":"Wang Z-J et al (2023) Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer\u2019s disease via the GLP-1R\/SIRT1\/GLUT4 pathway. Neuropharmacology 240:109716. https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109716","journal-title":"Neuropharmacology"},{"issue":"S9","key":"5505_CR123","doi-asserted-by":"publisher","DOI":"10.1002\/alz.057848","volume":"17","author":"P Edison","year":"2021","unstructured":"Edison P et al (2021) Evaluation of liraglutide in the treatment of Alzheimer\u2019s disease. Alzheimers Dement 17(S9):e057848. https:\/\/doi.org\/10.1002\/alz.057848","journal-title":"Alzheimers Dement"},{"issue":"1","key":"5505_CR124","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","volume":"17","author":"JL Cummings","year":"2025","unstructured":"Cummings JL et al (2025) evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther 17(1):14. https:\/\/doi.org\/10.1186\/s13195-024-01666-7","journal-title":"Alzheimer's Res Ther"},{"issue":"2","key":"5505_CR125","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3233\/jad-191302","volume":"75","author":"ST Henderson","year":"2020","unstructured":"Henderson ST et al (2020) A Placebo-controlled, parallel-group, randomized clinical trial of AC-1204 in mild-to-moderate Alzheimer\u2019s disease. J Alzheimers Dis 75(2):547\u2013557. https:\/\/doi.org\/10.3233\/jad-191302","journal-title":"J Alzheimers Dis"},{"key":"5505_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13020191","author":"Z Fi\u0161ar","year":"2024","unstructured":"Fi\u0161ar Z, Hroudov\u00e1 J (2024) CoQ(10) and mitochondrial dysfunction in Alzheimer\u2019s disease. Antioxidants (Basel). https:\/\/doi.org\/10.3390\/antiox13020191","journal-title":"Antioxidants (Basel)"},{"issue":"1","key":"5505_CR127","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12974-019-1627-9","volume":"16","author":"W Zhao","year":"2019","unstructured":"Zhao W et al (2019) Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. J Neuroinflammation 16(1):230. https:\/\/doi.org\/10.1186\/s12974-019-1627-9","journal-title":"J Neuroinflammation"},{"key":"5505_CR128","doi-asserted-by":"publisher","DOI":"10.3389\/fnint.2021.747901","volume":"15","author":"NT Nhu","year":"2022","unstructured":"Nhu NT et al (2022) Neuroprotective effects of a small mitochondrially-targeted tetrapeptide elamipretide in neurodegeneration. Front Integr Neurosci 15:747901","journal-title":"Front Integr Neurosci"},{"key":"5505_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-019-1627-9","volume":"16","author":"W Zhao","year":"2019","unstructured":"Zhao W et al (2019) Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. J Neuroinflammation 16:1\u201319","journal-title":"J Neuroinflammation"},{"issue":"6","key":"5505_CR130","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0286887","volume":"18","author":"S Wu","year":"2023","unstructured":"Wu S et al (2023) Outcomes and clinical implications of intranasal insulin on cognition in humans: a systematic review and meta-analysis. PLoS ONE 18(6):e0286887. https:\/\/doi.org\/10.1371\/journal.pone.0286887","journal-title":"PLoS ONE"},{"key":"5505_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.963933","author":"C Long","year":"2022","unstructured":"Long C et al (2022) Efficacy of intranasal insulin in improving cognition in mild cognitive impairment or dementia: a systematic review and meta-analysis. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2022.963933","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"5505_CR132","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13195-017-0307-1","volume":"9","author":"R Ghosh","year":"2017","unstructured":"Ghosh R, Tabrizi SJ (2017) Gene suppression approaches to neurodegeneration. Alzheimer\u2019s Res Ther 9(1):82. https:\/\/doi.org\/10.1186\/s13195-017-0307-1","journal-title":"Alzheimer's Res Ther"},{"issue":"3","key":"5505_CR133","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/brain\/awab423","volume":"145","author":"J-B de Brunet Courssou","year":"2021","unstructured":"de Brunet Courssou J-B et al (2021) Antisense therapies in neurological diseases. Brain 145(3):816\u2013831. https:\/\/doi.org\/10.1093\/brain\/awab423","journal-title":"Brain"},{"issue":"12","key":"5505_CR134","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jamaneurol.2023.3861","volume":"80","author":"AL Edwards","year":"2023","unstructured":"Edwards AL et al (2023) Exploratory tau biomarker results from a multiple ascending-dose study of BIIB080 in Alzheimer disease: a randomized clinical trial. JAMA Neurol 80(12):1344\u20131352","journal-title":"JAMA Neurol"},{"issue":"S6","key":"5505_CR135","doi-asserted-by":"publisher","DOI":"10.1002\/alz.084521","volume":"20","author":"S Cohen","year":"2024","unstructured":"Cohen S et al (2024) Single ascending dose results from an ongoing Phase 1 study of mivelsiran (ALN-APP), the first investigational RNA interference therapeutic targeting amyloid precursor protein for Alzheimer\u2019s disease. Alzheimers Dement 20(S6):e084521. https:\/\/doi.org\/10.1002\/alz.084521","journal-title":"Alzheimers Dement"},{"issue":"1","key":"5505_CR136","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.phrs.2009.10.002","volume":"61","author":"ST Lim","year":"2010","unstructured":"Lim ST, Airavaara M, Harvey BK (2010) Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS. Pharmacol Res 61(1):14\u201326. https:\/\/doi.org\/10.1016\/j.phrs.2009.10.002","journal-title":"Pharmacol Res"},{"issue":"12","key":"5505_CR137","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.2174\/0118715273283786240408034408","volume":"23","author":"S Tripathi","year":"2024","unstructured":"Tripathi S et al (2024) CRISPR\/Cas9 gene editing: a novel approach towards Alzheimer\u2019s disease treatment. CNS Neurol Disord Drug Targets 23(12):1405\u20131424. https:\/\/doi.org\/10.2174\/0118715273283786240408034408","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"5505_CR138","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3233\/JAD-215699","volume":"87","author":"CK Kim","year":"2022","unstructured":"Kim CK et al (2022) Alzheimer\u2019s disease: key insights from two decades of clinical trial failures. J Alzheimers Dis 87:83\u2013100. https:\/\/doi.org\/10.3233\/JAD-215699","journal-title":"J Alzheimers Dis"},{"key":"5505_CR139","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00373","author":"WM Pardridge","year":"2020","unstructured":"Pardridge WM (2020) Blood-brain barrier and delivery of protein and gene therapeutics to brain. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2019.00373","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"5505_CR140","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/abt\/tbac028","volume":"5","author":"P Zhao","year":"2022","unstructured":"Zhao P, Zhang N, An Z (2022) Engineering antibody and protein therapeutics to cross the blood\u2013brain barrier. Antib Ther 5(4):311\u2013331. https:\/\/doi.org\/10.1093\/abt\/tbac028","journal-title":"Antib Ther"},{"issue":"1","key":"5505_CR141","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12951-025-03247-8","volume":"23","author":"J Liu","year":"2025","unstructured":"Liu J et al (2025) The blood\u2013brain barriers: novel nanocarriers for central nervous system diseases. J Nanobiotechnology 23(1):146. https:\/\/doi.org\/10.1186\/s12951-025-03247-8","journal-title":"J Nanobiotechnology"},{"issue":"11","key":"5505_CR142","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15112599","volume":"15","author":"SK Niazi","year":"2023","unstructured":"Niazi SK (2023) Non-invasive drug delivery across the blood\u2013brain barrier: a prospective analysis. Pharmaceutics 15(11):2599","journal-title":"Pharmaceutics"},{"issue":"1","key":"5505_CR143","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","volume":"8","author":"D Wu","year":"2023","unstructured":"Wu D et al (2023) The blood\u2013brain barrier: structure, regulation and drug delivery. Signal Transduct Target Ther 8(1):217. https:\/\/doi.org\/10.1038\/s41392-023-01481-w","journal-title":"Signal Transduct Target Ther"},{"key":"5505_CR144","doi-asserted-by":"publisher","DOI":"10.3389\/fddev.2024.1360302","author":"AS Haqqani","year":"2024","unstructured":"Haqqani AS, B\u00e9langer K, Stanimirovic DB (2024) Receptor-mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria. Front Drug Deliv. https:\/\/doi.org\/10.3389\/fddev.2024.1360302","journal-title":"Front Drug Deliv"},{"key":"5505_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121949","volume":"293","author":"FU Rehman","year":"2023","unstructured":"Rehman FU et al (2023) Exosomes based strategies for brain drug delivery. Biomaterials 293:121949. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121949","journal-title":"Biomaterials"},{"key":"5505_CR146","doi-asserted-by":"publisher","first-page":"5380346","DOI":"10.1155\/2020\/5380346","volume":"2020","author":"AE Oxford","year":"2020","unstructured":"Oxford AE, Stewart ES, Rohn TT (2020) Clinical trials in Alzheimer\u2019s disease: a hurdle in the path of remedy. Int J Alzheimers Dis 2020:5380346. https:\/\/doi.org\/10.1155\/2020\/5380346","journal-title":"Int J Alzheimers Dis"},{"issue":"11","key":"5505_CR147","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H et al (2023) Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain 146(11):4414\u20134424. https:\/\/doi.org\/10.1093\/brain\/awad188","journal-title":"Brain"},{"issue":"18","key":"5505_CR148","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1016\/j.neuron.2023.05.017","volume":"111","author":"H Hampel","year":"2023","unstructured":"Hampel H et al (2023) Blood-based biomarkers for Alzheimer\u2019s disease: current state and future use in a transformed global healthcare landscape. Neuron 111(18):2781\u20132799","journal-title":"Neuron"},{"issue":"1","key":"5505_CR149","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-024-00705-z","volume":"19","author":"S Mravinacov\u00e1","year":"2024","unstructured":"Mravinacov\u00e1 S et al (2024) CSF protein ratios with enhanced potential to reflect Alzheimer\u2019s disease pathology and neurodegeneration. Mol Neurodegener 19(1):15.10.1186\/s13024-024-00705-z","journal-title":"Mol Neurodegener"},{"issue":"1","key":"5505_CR150","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1591-0","volume":"20","author":"C Wattmo","year":"2020","unstructured":"Wattmo C, Blennow K, Hansson O (2020) Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer\u2019s disease. BMC Neurol 20(1):10.10.1186\/s12883-019-1591-0","journal-title":"BMC Neurol"},{"key":"5505_CR151","unstructured":"Bateman, R.J., et al., (2025) Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer\u2019s disease: an open label extension of the phase 2\/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial. medRxiv, p. 2024.10. 29.24316289"},{"issue":"11","key":"5505_CR152","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1831","volume":"10","author":"J Guo","year":"2020","unstructured":"Guo J et al (2020) Memantine, donepezil, or combination therapy\u2014what is the best therapy for Alzheimer\u2019s disease? A network meta-analysis. Brain Behav 10(11):e01831","journal-title":"Brain Behav"},{"key":"5505_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.nanoso.2019.100370","volume":"19","author":"F Salahpour\u00a0Anarjan","year":"2019","unstructured":"Salahpour\u00a0Anarjan F (2019) Active targeting drug delivery nanocarriers: ligands. Nano-Struct Nano-Objects 19:100370. https:\/\/doi.org\/10.1016\/j.nanoso.2019.100370","journal-title":"Nano-Struct Nano-Objects"},{"key":"5505_CR154","doi-asserted-by":"publisher","DOI":"10.1177\/2041731419897460","volume":"11","author":"GZ Jin","year":"2020","unstructured":"Jin GZ et al (2020) Targeting with nanoparticles for the therapeutic treatment of brain diseases. J Tissue Eng 11:2041731419897460.10.1177\/2041731419897460","journal-title":"J Tissue Eng"},{"key":"5505_CR155","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16040481","author":"S Gandhi","year":"2024","unstructured":"Gandhi S et al (2024) Nasal delivery to the brain: harnessing nanoparticles for effective drug transport. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics16040481","journal-title":"Pharmaceutics"},{"issue":"11","key":"5505_CR156","doi-asserted-by":"publisher","DOI":"10.1002\/smsc.202400280","volume":"4","author":"M Kim","year":"2024","unstructured":"Kim M et al (2024) Transformative impact of nanocarrier-mediated drug delivery: overcoming biological barriers and expanding therapeutic horizons. Small Science 4(11):2400280. https:\/\/doi.org\/10.1002\/smsc.202400280","journal-title":"Small Science"},{"issue":"18","key":"5505_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e37533","volume":"10","author":"N Rouhi","year":"2024","unstructured":"Rouhi N et al (2024) A comprehensive review of advanced focused ultrasound (FUS) microbubbles-mediated treatment of Alzheimer\u2019s disease. Heliyon 10(18):e37533. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37533","journal-title":"Heliyon"},{"issue":"1","key":"5505_CR158","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-021-00269-8","volume":"10","author":"SH Park","year":"2021","unstructured":"Park SH et al (2021) Extensive frontal focused ultrasound mediated blood-brain barrier opening for the treatment of Alzheimer\u2019s disease: a proof-of-concept study. Transl Neurodegener 10(1):44.10.1186\/s40035-021-00269-8","journal-title":"Transl Neurodegener"},{"key":"5505_CR159","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14040823","author":"N \u00d6sterlund","year":"2022","unstructured":"\u00d6sterlund N, W\u00e4rml\u00e4nder S, Gr\u00e4slund A (2022) Cell-penetrating peptides with unexpected anti-amyloid properties. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics14040823","journal-title":"Pharmaceutics"},{"key":"5505_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104974","volume":"144","author":"R Kandimalla","year":"2023","unstructured":"Kandimalla R et al (2023) Exosome-based approaches in the management of Alzheimer\u2019s disease. Neurosci Biobehav Rev 144:104974. https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104974","journal-title":"Neurosci Biobehav Rev"},{"key":"5505_CR161","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216288","author":"AE Alkhalifa","year":"2023","unstructured":"Alkhalifa AE et al (2023) Blood-brain barrier breakdown in Alzheimer\u2019s disease: mechanisms and targeted strategies. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms242216288","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5505_CR162","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-021-00234-5","volume":"10","author":"X Ding","year":"2021","unstructured":"Ding X et al (2021) Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer\u2019s disease: a systematic review and meta-analysis. Transl Neurodegener 10(1):10.10.1186\/s40035-021-00234-5","journal-title":"Transl Neurodegener"},{"issue":"1","key":"5505_CR163","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-03084-7","volume":"14","author":"C della Monica","year":"2024","unstructured":"della Monica C et al (2024) P-tau217 and other blood biomarkers of dementia: variation with time of day. Transl Psychiatry 14(1):373. https:\/\/doi.org\/10.1038\/s41398-024-03084-7","journal-title":"Transl Psychiatry"},{"issue":"4","key":"5505_CR164","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/alz.12724","volume":"19","author":"P Chatterjee","year":"2023","unstructured":"Chatterjee P et al (2023) Plasma A\u03b242\/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer\u2019s disease continuum: a cross-sectional and longitudinal study in the AIBL cohort. Alzheimers Dement 19(4):1117\u20131134. https:\/\/doi.org\/10.1002\/alz.12724","journal-title":"Alzheimers Dement"},{"issue":"1","key":"5505_CR165","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01523-w","volume":"9","author":"YK Adlakha","year":"2023","unstructured":"Adlakha YK (2023) Human 3D brain organoids: steering the demolecularization of brain and neurological diseases. Cell Death Discov 9(1):221.10.1038\/s41420-023-01523-w","journal-title":"Cell Death Discov"},{"issue":"6","key":"5505_CR166","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/ame2.12487","volume":"7","author":"S Neziri","year":"2024","unstructured":"Neziri S et al (2024) Animal models in neuroscience with alternative approaches: evolutionary, biomedical, and ethical perspectives. Anim Models Exp Med 7(6):868\u2013880. https:\/\/doi.org\/10.1002\/ame2.12487","journal-title":"Anim Models Exp Med"},{"issue":"1","key":"5505_CR167","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22624-z","volume":"12","author":"D Baglietto-Vargas","year":"2021","unstructured":"Baglietto-Vargas D et al (2021) Generation of a humanized A\u03b2 expressing mouse demonstrating aspects of Alzheimer\u2019s disease-like pathology. Nat Commun 12(1):2421.10.1038\/s41467-021-22624-z","journal-title":"Nat Commun"},{"issue":"1","key":"5505_CR168","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1038\/s41467-020-15411-9","volume":"11","author":"R Xu","year":"2020","unstructured":"Xu R et al (2020) Human iPSC-derived mature microglia retain their identity and functionally integrate in the chimeric mouse brain. Nat Commun 11(1):1577. https:\/\/doi.org\/10.1038\/s41467-020-15411-9","journal-title":"Nat Commun"},{"issue":"1","key":"5505_CR169","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-025-00823-2","volume":"20","author":"L Serneels","year":"2025","unstructured":"Serneels L et al (2025) A versatile mouse model to advance human microglia transplantation research in neurodegenerative diseases. Mol Neurodegener 20(1):29. https:\/\/doi.org\/10.1186\/s13024-025-00823-2","journal-title":"Mol Neurodegener"},{"key":"5505_CR170","doi-asserted-by":"publisher","DOI":"10.3389\/fddsv.2022.1019706","author":"M DiNuzzo","year":"2022","unstructured":"DiNuzzo M (2022) How artificial intelligence enables modeling and simulation of biological networks to accelerate drug discovery. Frontiers in Drug Discov. https:\/\/doi.org\/10.3389\/fddsv.2022.1019706","journal-title":"Frontiers in Drug Discov"},{"issue":"3","key":"5505_CR171","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s11030-021-10326-z","volume":"26","author":"C Selvaraj","year":"2022","unstructured":"Selvaraj C, Chandra I, Singh SK (2022) Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries. Mol Divers 26(3):1893\u20131913. https:\/\/doi.org\/10.1007\/s11030-021-10326-z","journal-title":"Mol Divers"},{"issue":"1","key":"5505_CR172","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21330-0","volume":"12","author":"S Rodriguez","year":"2021","unstructured":"Rodriguez S et al (2021) Machine learning identifies candidates for drug repurposing in Alzheimer\u2019s disease. Nat Commun 12(1):1033. https:\/\/doi.org\/10.1038\/s41467-021-21330-0","journal-title":"Nat Commun"},{"issue":"1","key":"5505_CR173","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41467-021-21330-0","volume":"12","author":"S Rodriguez","year":"2021","unstructured":"Rodriguez S et al (2021) Machine learning identifies candidates for drug repurposing in Alzheimer\u2019s disease. Nat Commun 12(1):1033. https:\/\/doi.org\/10.1038\/s41467-021-21330-0","journal-title":"Nat Commun"},{"key":"5505_CR174","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae445","author":"C Birkenbihl","year":"2024","unstructured":"Birkenbihl C et al (2024) Deep learning-based patient stratification for prognostic enrichment of clinical dementia trials. Brain Commun. https:\/\/doi.org\/10.1093\/braincomms\/fcae445","journal-title":"Brain Commun"},{"key":"5505_CR175","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155811","volume":"132","author":"M Song","year":"2024","unstructured":"Song M et al (2024) Gomisin N rescues cognitive impairment of Alzheimer\u2019s disease by targeting GSK3\u03b2 and activating Nrf2 signaling pathway. Phytomedicine 132:155811. https:\/\/doi.org\/10.1016\/j.phymed.2024.155811","journal-title":"Phytomedicine"},{"issue":"1","key":"5505_CR176","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1172\/jci64516","volume":"123","author":"PT Ly","year":"2013","unstructured":"Ly PT et al (2013) Inhibition of GSK3\u03b2-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest 123(1):224\u2013235. https:\/\/doi.org\/10.1172\/jci64516","journal-title":"J Clin Invest"},{"issue":"1","key":"5505_CR177","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54557-5","volume":"9","author":"G Griebel","year":"2019","unstructured":"Griebel G et al (2019) The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer\u2019s disease in rodents. Sci Rep 9(1):18045. https:\/\/doi.org\/10.1038\/s41598-019-54557-5","journal-title":"Sci Rep"},{"issue":"21","key":"5505_CR178","doi-asserted-by":"publisher","first-page":"9600","DOI":"10.1021\/acs.jmedchem.9b01030","volume":"62","author":"V Bernard-Gauthier","year":"2019","unstructured":"Bernard-Gauthier V et al (2019) Structural basis for achieving GSK-3\u03b2 inhibition with high potency, selectivity, and brain exposure for positron emission tomography imaging and drug discovery. J Med Chem 62(21):9600\u20139617. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01030","journal-title":"J Med Chem"},{"key":"5505_CR179","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.152166","volume":"775","author":"A Choudhury","year":"2025","unstructured":"Choudhury A et al (2025) Structure-guided discovery of tau-phosphorylating kinase DYRK1A inhibitors for therapeutic targeting of neuroinflammatory diseases: insights from microsecond MD simulation and MMPBSA analyses. Biochem Biophys Res Commun 775:152166. https:\/\/doi.org\/10.1016\/j.bbrc.2025.152166","journal-title":"Biochem Biophys Res Commun"},{"key":"5505_CR180","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232113098","author":"N Stern","year":"2022","unstructured":"Stern N et al (2022) Dual inhibitors of AChE and BACE-1 for reducing A\u03b2 in Alzheimer\u2019s disease: from in silico to in vivo. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232113098","journal-title":"Int J Mol Sci"},{"key":"5505_CR181","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bbr.2015.03.029","volume":"287","author":"V Puri","year":"2015","unstructured":"Puri V et al (2015) The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer\u2019s disease mouse model. Behav Brain Res 287:96\u201399. https:\/\/doi.org\/10.1016\/j.bbr.2015.03.029","journal-title":"Behav Brain Res"},{"key":"5505_CR182","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26083473","author":"HW Querfurth","year":"2025","unstructured":"Querfurth HW et al (2025) Target validation studies of PS48, a PDK-1 allosteric agonist, for the treatment of Alzheimer\u2019s disease phenotype in APP\/PS1 transgenic mice. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26083473","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5505_CR183","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1039\/C4MT00252K","volume":"7","author":"MR Jones","year":"2015","unstructured":"Jones MR et al (2015) Modulation of the A\u03b2 peptide aggregation pathway by KP1019 limits A\u03b2-associated neurotoxicity. Metallomics 7(1):129\u2013135","journal-title":"Metallomics"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05505-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05505-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05505-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:02:37Z","timestamp":1778922157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-026-05505-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":157,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["5505"],"URL":"https:\/\/doi.org\/10.1007\/s11010-026-05505-1","relation":{},"ISSN":["1573-4919"],"issn-type":[{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}